Tagged with IMC

Five Biotechs to Know in Belgium

Belgium Five Biotechs to Know in Belgium

Belgium With over 140 operating biotech companies representing almost a quarter of Europe’s biotech market and a strong network of universities and research institutes, Belgium boasts a solid biotech ecosystem that continues to thrive despite recent downturns in biotech financing. Beyond more well-known players like Argenx, acquired by Sanofi, and Galapagos,…

China China Pharma Roundup: Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?

China The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in Alzheimer’s; Innovent’s tie-up with Ascentage; Biogen’s USD 125 million midstage MS drug pact with InnoCare; and Everest Medicines’ partnership with social media giant Tencent. Sinopharm Tops Ranking of…

Global 2020’s Top 7 Biotech IPOs in Profile

Global Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. Notably, six of the seven companies are from China, pointing to the massive growth of the Chinese biotech market. Remegen RemeGen,…

A New Approach to Rare Diseases in Canada

Canada A New Approach to Rare Diseases in Canada

Canada Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada. Especially in smaller provinces, it’s virtually impossible to predictably manage the affordability and accessibility of drugs necessary to treat rare disease Around the world, rare diseases are becoming easier…

Interview: Pamela C. Fralick – President, Innovative Medicines Canada (IMC)

Canada Interview: Pamela C. Fralick – President, Innovative Medicines Canada (IMC)

Canada Pamela C. Fralick, President of Innovative Medicines Canada (IMC), the innovative pharma association in Canada, looks back on her first half year in position, the challenges of navigating Canada’s complex and multifaceted health ecosystem, and her goal of bringing together all healthcare stakeholders in much-needed dialogue on how to improve…

Interview: Dr. Jan Frederic Kesselhut – CEO, Servier Hungary

Pharma Interview: Dr. Jan Frederic Kesselhut – CEO, Servier Hungary

Pharma The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute of Medicinal Chemistry (SRIMC) in Hungary plays in the group’s overall R&D activities. He also elaborates on the crucial importance…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page